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Introduction
The pathophysiology of hypertension is not multifactorial in 
nature, and there is a complex interplay of mechanisms of 
control and counter-regulatory responses activated by drugs. 
The problem for clinicians is that it is not really possible to 
recognise the various clinical phenotypes of hypertension. 
In other words, the heterogeneity of hypertension remains 
a clinical problem.1 Current overwhelming evidence is that 
the most important treatment concept in the management 
of hypertension is that treatment should reduce blood 
pressure to goal levels.2 The majority of hypertensive 
patients will need two or more antihypertensive drugs to 
control their blood pressure at goal. Conceptually, a strong 
case can be made for the early use of combination therapy 
in the treatment of hypertension.3
Choosing a combination: What is the 
problem?
The essential problem is that there are very little data 
from prospective randomised controlled clinical trials that 
test specific combinations against one another, to guide 
clinicians in choosing the “superior” combination. Most of 
the trials that have been carried out tested one drug against 
another, and then other drugs were added to both treatment 
arms. Also, in most trials, the second added drug (to both 
the treatment arms) was the same.
However, there are recommendations in the literature 
on combinations.3 These are depicted in the Table I as 
preferred, acceptable, and unacceptable combinations. 
The best evidence from which claims can be made from 
outcomes in favour of a particular combination regimen, 
derives from four trials:3
•	 LIFE (Losartan Intervention For Endpoint reduction in 
hypertension) study: angiotensin- receptor blocker (ARB) 
trial
•	 ASCOT (Anglo-Scandinavian Cardiac Outcomes Trial): 
angiotensin-converting enzyme (ACE) inhibitors trial
•	 ACCOMPLISH (Avoiding Cardiovascular events through 
COMbination therapy in Patients living with Systolic 
Hypertension) trial: ACE inhibitor trial
•	 VALUE (Valsartan Antihypertension Long-term use 
Evaluation) trial: ARB trial.
What evidence is there for angiotensin-
receptor blocker combinations?
Currently, dual renin-angiotensin aldosterone system 
(RAAS) blockade, specifically an ACE inhibitor plus an ARB, 
should not be used for the treatment of hypertension, as 
there are no real benefits. Moreover, the risks may outweigh 
the benefits.4 This was demonstrated in the well-known 
ONTARGET (Ongoing Telmisartan Alone and in Combination 
with Ramipril Global Endpoint Trial). 
In the LIFE trial, 9  193 hypertensives were treated either 
with an ARB (losartan) or beta blocker (atenolol), but in 
both groups, hydrochlorothiazine (HCTZ) was added in 
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Table I: Drug combinations in hypertension3
Preferred combinations
ACEa inhibitor plus diuretic
ARBb plus diuretic
ACE inhibitor plus calcium-channel blocker
ARB plus calcium-channel blocker
Acceptable combinations
Beta blocker or diuretic (not a high dose)
Calcium-channel blocker (dihydropyridine) or beta blocker
Calcium-channel blocker or diuretic
Renin inhibitor or diuretic
Renin inhibitor or calcium-channel blocker
Dihydropyridine or non-dihydropiridine calcium-channel blocker
Unacceptable combinations
ACE inhibitor or ARB
Renin inhibitor or ARB
Renin inhibitor or ACE inhibitor
Calcium-channel blocker (non-dihydropyridine) or beta blocker
Centrally-acting agent or beta blocker
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the majority of patients.5 The combination of losartan plus 
HCTZ, as compared to the combination of atenolol plus 
HCTZ, reduced the composite primary cardiovascular end-
point by 13%. The major benefit of losartan plus HCTZ 
was in the secondary end-point of stroke (a component of 
the primary end-point), which was reduced by 25%. This 
achieved result occurred against the background of an 
equally reduced level of blood pressure.
In the VALUE trial, 15 245 hypertensives received either an 
ARB (valsartan) or amlodipine (calcium-channel blocker), 
and to each arm, HCTZ could be added to control blood 
pressure over 4.2 years.6 The primary composite end-
point of cardiac morbidity and mortality was similar in the 
two arms, comparing valsartan plus HCTZ vs. amlodipine 
plus HCTZ, but early, better control of blood pressure in 
the amlodipine arm led to less myocardial infarctions. This 
trial also linked to the cardiovascular benefit of early blood 
pressure control in high-risk hypertensives.
The cumulative evidence from these trials supports the view 
that an ARB plus calcium-channel blocker combination is 
likely to be associated with better cardiovascular outcomes, 
than combinations containing beta blockers and thiazide 
diuretics.3 Numerous factorial design studies have shown 
that the combination of a thiazide diuretic plus an ARB (many 
ARBs) results in fully additive blood pressure reduction. 
Diuretics activate the RAAS by depleting intravascular 
volume and addition of ARB, then attenuates this counter-
regulatory response, and mitigates the hypokalemia induced 
by the diuretic.
Numerous efficacy and tolerability studies on the 
combination of an ARB plus a calcium-channel blocker have 
been carried out, and demonstrated greater blood pressure 
reductions with the combinations, and significantly more 
patients achieving goal blood pressure.7 The combinations 
tested were amlodipine and valsartan, and amlodipine plus 
telmisartan, in varying fixed combinations. The combination 
of amlodipine plus candesartan, as compared to amlodipine 
alone, also showed increased efficacy for the combination.8 
It is foreseen that all ARBs on the market will be combined 
with a calcium-channel blocker. In a recent trial, 350 
hypertensives were treated with a calcium-channel blocker 
plus an ARB, or a calcium-channel plus a beta blocker, or 
a calcium-channel blocker plus a thiazide diuretic,9 and the 
clinical effects tested in these three arms. After 3.61 years 
of treatment, two thirds of the patients achieved target 
blood pressure, and the three combinations were equally 
effective in achieving goal blood pressure. Equally, all 
three combinations had the same reduction of the primary 
composite outcome of cardiovascular events.
In an efficacy and safety trial, an ARB plus calcium-
channel blocker plus HCTZ (triple combination) resulted in 
significantly more patients reaching goal blood pressure, 
than the combinations of the ARB plus HCTZ, or ARB plus 
calcium-channel blocker, or calcium-channel blocker plus 
HCTZ combinations.10 This study demonstrates that triple 
therapy (ARB plus calcium-channel blocker plus HCTZ) 
can be given safely, can achieve goal blood pressure more 
often, and can do so promptly.
In summary, there appears to be enough data to support 
the combination of an ARB plus a diuretic and/or a calcium-
channel blocker, either as two separate drugs, or in a fixed 
combination, with the aim of improving the percentage of 
hypertensive patients who can reach goal blood pressure.
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